Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co), which gained label expansion in January 2023 in the adjuvant setting, have broad applicability in many stages and settings of NSCLC and dominate the market, while biomarker-targeted therapeutics increasingly drive segmentation of the space. The range of drug-addressable disease drivers continues to expand, with the entry of KRAS inhibitors and the 2022 approval of Enhertu, the first targeted therapy for previously treated metastatic HER2-mutant NSCLC. Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus further new market entrants, will further drive competition in this commercially lucrative market.
Questions answered
- How will the recent and expected new market entrants shape the treatment landscapes across the various settings and stages (I-IV) of NSCLC?
- Which therapy options will dominate the commercially lucrative first-line metastatic NSCLC setting?
- What are the most promising pipeline products, and what is their forecast uptake and patient share in NSCLC?
- What are NSCLC’s key market drivers and constraints, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- October 2023
- September 2023
- May 2023
- April 2023
- December 2022
- Market Outlook
- Key findings
- Major-market share of drug classes in NSCLC: 2022
- Major-market share of drug classes in NSCLC: 2032
- Key current therapies in NSCLC: population positioning
- Emerging therapies in NSCLC: population positioning
- NSCLC SWOT analysis
- Market drivers and constraints
- What factors are driving the market for NSCLC?
- What factors are constraining the market for NSCLC?
- Drug-treatable population share and major-market sales share in NSCLC: 2022
- Drug-treatable population share and major-market sales share in NSCLC: 2032
- Major-market sales of drug classes in NSCLC: 2022-2032
- Major-market sales of select drugs in NSCLC: 2022-2032
- Major-market sales share of select drugs in NSCLC by patient population (all histologies): 2022 and 2032
- Segment-specific trends
- Stage IA NSCLC
- Stage IB-II NSCLC
- Stage III NSCLC
- Patient-share dynamics of select therapies in stage III NSCLC (adenocarcinoma), United States: 2022-2032
- Patient-share dynamics of key regimens in first-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
- Patient-share dynamics of immune checkpoint inhibitor-containing regimens in first-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
- Patient-share dynamics of key therapies in first-line EGFR-positive metastatic NSCLC (adenocarcinoma), United States: 2022-2032
- Patient-share dynamics of key therapies in first-line ALK-positive metastatic NSCLC (adenocarcinoma), United States: 2022-2032
- Patient-share dynamics of key regimens in second-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
- Patient-share dynamics of key regimens in third-line metastatic NSCLC (adenocarcinoma), United States: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Disease pathophysiology
- Progression of NSCLC
- Anatomy and histology of NSCLC
- Natural history of NSCLC
- Timing of genetic changes in NSCLC
- Staging and classification
- Classification of NSCLC
- Staging of NSCLC
- Key pathways and drug targets
- Key pathways and drug targets for NSCLC
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed incident cases of NSCLC by histology: 2022-2032
- Disease definition, methods, and sources used
- Diagnosed incident cases of adenocarcinoma by stage at diagnosis: 2022-2032
- Diagnosed incident cases of squamous cell carcinoma by stage at diagnosis: 2022-2032
- Diagnosed incident cases of large-cell and other types of NSCLC by stage at diagnosis: 2022-2032
- Diagnosed incident cases of NOS NSCLC by stage at diagnosis: 2022-2032
- Disease definition, methods, and sources used
- Recurrent incident cases of NSCLC by histology: 2022-2032
- Non-small-cell lung cancer patient flow
- Drug-treatable cases of adenocarcinoma NSCLC: 2022-2032
- Drug-treatable cases of large-cell, other, and NOS NSCLC: 2022-2032
- Drug-treatable cases of squamous cell NSCLC: 2022-2032
- Drug-treated cases of adenocarcinoma NSCLC: 2022-2032
- Drug-treated cases of large-cell, other, and NOS NSCLC: 2022-2032
- Drug-treated cases of squamous cell NSCLC: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for non-small-cell lung cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for non-small-cell lung cancer
- Current treatments used for non-small-cell lung cancer
- Market events impacting the use of key current therapies in non-small-cell lung cancer
- Key results from select clinical trials investigating Keytruda for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of non-small-cell lung cancer
- Expert insight: Keytruda
- Key results from select clinical trials investigating Opdivo for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of non-small-cell lung cancer
- Key results from select clinical trials investigating Opdivo combination therapies for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Opdivo combination therapies
- Key ongoing clinical trials of Opdivo combination therapies in the treatment of non-small-cell lung cancer
- Expert insight: Opdivo combination therapies
- Tecentriq
- Key results from select clinical trials investigating Tecentriq for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of non-small-cell lung cancer
- Expert insight: Tecentriq
- Key results from select clinical trials investigating Imfinzi for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Imfinzi
- Key ongoing clinical trials of Imfinzi in the treatment of non-small-cell lung cancer
- Expert insight: Imfinzi
- Key results from select clinical trials investigating Imfinzi plus Imjudo for the treatment of non-small-cell lung cancer
- Expert insight: Imfinzi plus Imjudo
- Key results from select clinical trials investigating Libtayo for the treatment of non-small-cell lung cancer
- Expert insight: Libtayo
- Key results from select clinical trials investigating Tagrisso for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tagrisso
- Key ongoing clinical trials of Tagrisso in the treatment of non-small-cell lung cancer
- Expert insight: Tagrisso
- Ongoing clinical development of erlotinib
- Key ongoing clinical trials of erlotinib in the treatment of non-small-cell lung cancer
- Key results from select clinical trials investigating Exkivity for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Exkivity
- Expert insight: Exkivity
- Rybrevant
- Key results from select clinical trials investigating Rybrevant for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Rybrevant
- Expert insight: Rybrevant
- Key results from select clinical trials investigating Alecensa for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Alecensa
- Key ongoing clinical trials of Alecensa in the treatment of non-small-cell lung cancer
- Expert insight: Alecensa
- Key results from select clinical trials investigating Alunbrig for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Alunbrig
- Expert insight: Alunbrig
- Key results from select clinical trials investigating Lorbrena / Lorviqua for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Lorbrena / Lorviqua
- Expert insight: Lorbrena / Lorviqua
- Key results from select clinical trials investigating Xalkori for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Xalkori
- Key ongoing clinical trials of Xalkori in the treatment of non-small-cell lung cancer
- Ongoing clinical development of Zykadia
- Expert insight: Zykadia
- Key results from select clinical trials investigating Rozlytrek for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Rozlytrek
- Key ongoing clinical trials of Rozlytrek in the treatment of non-small-cell lung cancer
- Expert insight: Rozlytrek
- Key results from select clinical trials investigating Retevmo / Retsevmo for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Retevmo / Retsevmo
- Key ongoing clinical trials of Retevmo / Retsevmo in the treatment of non-small-cell lung cancer
- Expert insight: Retevmo
- Key results from select clinical trials investigating Gavreto for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Gavreto
- Key ongoing clinical trials of Gavreto in the treatment of non-small-cell lung cancer
- Expert insights: RET inhibitors
- Key results from select clinical trials investigating Tabrecta for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tabrecta
- Key ongoing clinical trials of Tabrecta in the treatment of non-small-cell lung cancer
- Expert insight: Tabrecta
- Key results from select clinical trials investigating Tepmetko for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tepmetko
- Expert insight: MET inhibitors for non-small-cell lung cancer
- Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Lumakras / Lumykras
- Key ongoing clinical trials of Lumakras / Lumykras in the treatment of non-small-cell lung cancer
- Expert insight: Lumakras / Lumykras
- Key results from select clinical trials investigating Krazati for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Krazati
- Key ongoing clinical trials of Krazati in the treatment of non-small-cell lung cancer
- Expert insight: Krazati
- Key results from select clinical trials investigating Enhertu for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Enhertu
- Key ongoing clinical trials of Enhertu in the treatment of non-small-cell lung cancer
- Expert insight: Avastin
- Key results from select clinical trials investigating Cyramza for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Cyramza
- Key ongoing clinical trials of Cyramza in the treatment of non-small-cell lung cancer
- Medical practice
- Localized stage I/II and resectable and unresectable stage III non-small-cell lung cancer
- First-line metastatic nonsquamous non-small-cell lung cancer
- First-line metastatic squamous non-small-cell lung cancer
- Second- and third-line metastatic nonsquamous non-small-cell lung cancer
- Second- and third-line metastatic squamous non-small-cell lung cancer
- Treatment guidelines
- Patient characteristics influencing drug selection
- Treatment decision tree for early-stage (stage I - III) non-small-cell lung cancer
- Treatment decision tree for metastatic (stage IV) nonsquamous non-small-cell lung cancer with EGFR, ALK, BRAF V600E, ROS1, RET, or MET exon 14 skipping mutations
- Treatment decision tree metastatic (stage IV) nonsquamous non-small-cell lung cancer with KRAS G12C, HER2, or EGFR exon 20 insertion mutations, or without actionable mutations
- Treatment decision tree for metastatic (stage IV) squamous non-small-cell lung cancer
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in non-small-cell lung cancer
- Top unmet needs in non-small-cell lung cancer: current and future attainment
- Drug Pipeline
- Pipeline
- Regulatory milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for non-small-cell lung cancer
- Estimated market authorization dates of key emerging therapies for the treatment of non-small-cell lung cancer
- Key results from select clinical trials investigating Tevimbra for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Tevimbra
- Expectations for market authorization and sales opportunity of Tevimbra in non-small-cell lung cancer
- Key ongoing clinical trials of retifanlimab for the treatment of non-small-cell lung cancer
- Analysis of clinical development program for retifanlimab
- Expectations for market authorization and sales opportunity of retifanlimab in non-small-cell lung cancer
- Key results from select clinical trials investigating Jemperli for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Jemperli in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Jemperli
- Expectations for market authorization and sales opportunity of Jemperli in non-small-cell lung cancer
- Key results from select clinical trials investigating ivonescimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of ivonescimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ivonescimab
- Expectations for market authorization and sales opportunity of ivonescimab in non-small-cell lung cancer
- Key results from select clinical trials investigating fianlimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of fianlimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for fianlimab
- Expectations for market authorization and sales opportunity of fianlimab in non-small-cell lung cancer
- Key results from select clinical trials investigating tiragolumab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of tiragolumab for the treatment of non-small-cell lung cancer
- Analysis of clinical development program for tiragolumab
- Expert insight: tiragolumab
- Expectations for market authorization and sales opportunity of tiragolumab in non-small-cell lung cancer
- Key results from select clinical trials investigating vibostolimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of vibostolimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for vibostolimab
- Expert insight: vibostolimab
- Expectations for market authorization and sales opportunity of vibostolimab in non-small-cell lung cancer
- Key ongoing clinical trials of ociperlimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ociperlimab
- Expectations for market authorization and sales opportunity of ociperlimab in non-small-cell lung cancer
- Key results from select clinical trials investigating domvanalimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of domvanalimab for the treatment of non-small-cell lung cancer
- Analysis of clinical development program for domvanalimab
- Expectations for market authorization and sales opportunity of domvanalimab in non-small-cell lung cancer
- Key results from select clinical trials investigating oleclumab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of oleclumab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for oleclumab
- Expert insight: oleclumab
- Expectations for market authorization and sales opportunity of oleclumab in non-small-cell lung cancer
- Analysis of the clinical development program for monalizumab
- Expert insight: oleclumab and monalizumab in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of monalizumab in non-small-cell lung cancer
- Gotistobart
- Key results from select clinical trials for gotistobart
- Key ongoing trials of gotistobart
- Analysis of the clinical development program for gotistobart
- Expectations for market authorization and sales for gotistobart
- Key results from select clinical trials investigating lazertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of lazertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for lazertinib
- Expert insight: lazertinib
- Expectations for market authorization and sales opportunity of lazertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating aumolertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of aumolertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for aumolertinib
- Expectations for market authorization and sales opportunity of aumolertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating furmonertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of furmonertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for furmonertinib
- Expectations for market authorization and sales opportunity of furmonertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating sunvozertinib for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for sunvozertinib
- Expectations for market authorization and sales opportunity of sunvozertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating zipalertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of zipalertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for zipalertinib
- Expectations for market authorization and sales opportunity of zipalertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating ensartinib for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ensartinib
- Expectations for market authorization and sales opportunity of ensartinib in non-small-cell lung cancer
- Key results from select clinical trials investigating Bravtovi and Mektovi combination therapy for the treatment of non-small-cell lung cancer
- Expert insight: Braftovi and Mektovi
- Expectations for market authorization and sales opportunity of Bravtovi and Mektovi combination therapy in non-small-cell lung cancer
- Key results from select clinical trials investigating avutometinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of avutometinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for avutometinib
- Expectations for market authorization and sales opportunity of avutometinib in non-small-cell lung cancer
- Key results from select clinical trials investigating repotrectinib for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for repotrectinib
- Expert insight: repotrectinib
- Expectations for market authorization and sales opportunity of repotrectinib in non-small-cell lung cancer
- Key results from select clinical trials investigating taletrectinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of taletrectinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for taletrectinib
- Expectations for market authorization and sales opportunity of taletrectinib in non-small-cell lung cancer
- Key results from select clinical trials investigating NVL-520 for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for NVL-520
- Expectations for market authorization and sales opportunity of NVL-520 in non-small-cell lung cancer
- Key results from select clinical trials investigating savolitinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of savolitinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for savolitinib
- Expert insight: savolitinib
- Expectations for market authorization and sales opportunity of savolitinib in non-small-cell lung cancer
- Key results from select clinical trials investigating telisotuzumab vedotin for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of telisotuzumab vedotin in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for telisotuzumab vedotin
- Expert insight: telisotuzumab vedotin
- Expectations for market authorization and sales opportunity of telisotuzumab vedotin in non-small-cell lung cancer
- Key results from select clinical trials investigating opnurasib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of opnurasib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for opnurasib
- Expert insight: emerging KRAS inhibitors
- Expectations for market authorization and sales opportunity of opnurasib in non-small-cell lung cancer
- Key results from select clinical trials investigating divarasib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of divarasib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for divarasib
- Expectations for market authorization and sales opportunity of divarasib in non-small-cell lung cancer
- Key results from select clinical trials investigating pyrotinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of pyrotinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for pyrotinib
- Expectations for market authorization and sales opportunity of pyrotinib in non-small-cell lung cancer
- Key results of select clinical trials investigating ceralasertib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of ceralasertib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ceralasertib
- Expert insight: ceralasertib
- Expectations for market authorization and sales opportunity of ceralasertib in non-small-cell lung cancer
- Key results from select clinical trials investigating tusamitamab ravtansine for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of tusamitamab ravtansine in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for tusamitamab ravtansine
- Expert insight: use of tusamitamab ravtansine in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of tusamitamab ravtansine in non-small-cell lung cancer
- Key results from select clinical trials investigating patritumab deruxtecan for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of patritumab deruxtecan in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for patritumab deruxtecan
- Expert insight: use of patritumab deruxtecan in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of patritumab deruxtecan in non-small-cell lung cancer
- Key results from select clinical trials investigating datopotamab deruxtecan for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of datopotamab deruxtecan in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for datopotamab deruxtecan
- Expert insight: use of anti-TROP2 ADCs in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of datopotamab deruxtecan in non-small-cell lung cancer
- Key results from select clinical trials investigating Trodelvy for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Trodelvy in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Trodelvy
- Expectations for market authorization and sales opportunity of Trodelvy in non-small-cell lung cancer
- Key results from select clinical trials investigating lifileucel for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for lifileucel
- Expert insights: the use of lifileucel in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of lifileucel in non-small-cell lung cancer
- Key results from select clinical trials investigating OSE-2101 for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for OSE-2101
- Expert insight: use of OSE-2101 in the treatment of non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of OSE-2101 in non-small-cell lung cancer
- Key results from select clinical trials investigating Lenvima for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Lenvima
- Expert insight: Lenvima
- Expectations for market authorization and sales opportunity of Lenvima in non-small-cell lung cancer
- Key results from select clinical trials investigating plinabulin for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for plinabulin
- Expert insight: use of plinabulin in the treatment of non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of plinabulin in non-small-cell lung cancer
- Key ongoing clinical trials of Lynparza in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Lynparza
- Expert insight: Lynparza
- Expectations for market authorization and sales opportunity of Lynparza in non-small-cell lung cancer
- Key results from select clinical trials investigating Zejula for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Zejula in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Zejula
- Expectations for market authorization and sales opportunity of Zejula in non-small-cell lung cancer
- Key results from select clinical trials investigating nogapendekin alfa (N-803) for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of nogapendekin alfa (N-803) in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for nogapendekin alfa (N-803)
- Expectations for market authorization and sales opportunity of nogapendekin alfa (N-803) in non-small-cell lung cancer
- Early-phase pipeline analysis
- Select compounds in Phase 2 development for non-small-cell lung cancer
- Key findings
- Access and Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in NSCLC: United States
- General reimbursement environment: United States
- Key market access considerations in NSCLC: EU5
- General reimbursement environment: EU5
- Key market access considerations in NSCLC: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Bibliography
- Key Findings
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.